| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 15.51M | 13.25M | 15.37M | 13.78M | 6.41M | 4.29M | 
| Gross Profit | -3.96M | 5.15M | -21.75M | 20.63M | 11.24M | 4.25M | 
| EBITDA | -9.43M | -8.94M | -35.54M | -24.63M | -19.79M | -22.55M | 
| Net Income | -47.60M | -22.34M | -51.24M | -33.79M | -26.47M | -25.10M | 
| Balance Sheet | ||||||
| Total Assets | 84.97M | 78.79M | 92.77M | 129.47M | 139.66M | 101.79M | 
| Cash, Cash Equivalents and Short-Term Investments | 60.00K | 10.00K | 1.64M | 765.00K | 1.91M | 3.10M | 
| Total Debt | 72.36M | 75.84M | 72.47M | 60.97M | 47.16M | 680.00K | 
| Total Liabilities | 78.65M | 81.56M | 78.85M | 70.20M | 54.76M | 9.92M | 
| Stockholders Equity | 6.32M | -2.77M | 13.92M | 59.26M | 84.90M | 91.87M | 
| Cash Flow | ||||||
| Free Cash Flow | -13.90M | -9.80M | -17.69M | -25.94M | -65.60M | -37.10M | 
| Operating Cash Flow | -13.65M | -9.64M | -15.19M | -22.84M | -20.43M | -20.83M | 
| Investing Cash Flow | 3.43M | -157.00K | 1.18M | -28.00K | -45.16M | -17.08M | 
| Financing Cash Flow | 8.53M | 8.17M | 14.77M | 21.71M | 64.41M | 39.47M | 
Cann Group Limited has announced a capital raising initiative through the offer of new ordinary shares and options to sophisticated and professional investors. This move is aimed at strengthening the company’s financial position and supporting its growth strategy in the medicinal cannabis sector. The capital raising is expected to have a significant impact on Cann Group’s operations by providing the necessary funds to expand its market presence and enhance its industry positioning.
Cann Group Limited has announced a proposed issue of securities, including options and ordinary shares, as part of a securities purchase plan and placement. This move aims to raise capital, potentially strengthening the company’s financial position and supporting its growth initiatives in the medicinal cannabis sector.
Cann Group Limited has announced a significant restructuring of its debt and a capital raise, which includes a major debt forgiveness agreement with National Australia Bank, reducing its outstanding loan balance by 81%. The company has also secured a new loan from an existing lender and commitments for a $9 million capital raise through institutional placement and a share purchase plan. This financial restructuring is expected to improve Cann Group’s financial stability and market position, with projected revenue growth and a reduction in EBITDA losses by FY26.
Cann Group Limited has requested a trading halt on its securities pending an announcement related to its debt restructuring and capital raising activities. This move is intended to help the company manage its continuous disclosure obligations and is expected to have implications for its financial strategy and market positioning.
Cann Group Limited has announced a short-term extension of its debt facilities with National Australia Bank, moving the expiry date from 15 October 2025 to 31 October 2025. This extension allows the company additional time to engage in refinancing discussions and evaluate options that align with its long-term financial strategy, potentially impacting its operational stability and financial planning.
Cann Group Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to ASX Corporate Governance Council’s principles and recommendations. This announcement underscores Cann Group’s commitment to transparency and accountability, potentially strengthening its position in the market and providing reassurance to stakeholders regarding its governance practices.
Cann Group Limited has announced a new issuance of 28,414,222 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) as of September 26, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and support its ongoing operations and growth initiatives in the medicinal cannabis sector.
Cann Group Limited has announced the quotation of 11,546,780 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 25, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence, which could have implications for its operations and stakeholders by providing additional resources for growth and development.
Cann Group Limited announced a positive EBITDA for August 2025, marking a significant milestone since the commissioning of its Mildura facility in 2022. The company’s growth is driven by strong B2B flower sales, expansion of its Botanitech product range, and increasing export opportunities, particularly in Europe. Cann is also enhancing its product portfolio with new offerings and has secured additional R&D funding, while progressing its refinancing initiatives to support future growth.
Cann Group Limited has received a Letter of Non-Waiver from National Australia Bank regarding its non-payment of interest and facility fees totaling $1,378,152, which were due in late August 2025. While NAB reserves its rights, it has decided not to take any action at this time. Cann Group is actively engaging with NAB and other financiers to address its financing arrangements and plans to update the market by the end of September 2025.
Cann Group Limited has announced the issuance of 12,306,575 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of September 3, 2025. This move reflects the company’s strategic efforts to enhance its capital structure and potentially expand its market presence, offering stakeholders an opportunity to engage with its growth trajectory.
Cann Group Limited reported its FY25 financial results, highlighting a significant increase in dried flower production and a 100% growth in revenue from its Botanitech brand. The company successfully reduced operating expenses by 35%, resulting in improved EBITDA and a reduced loss after tax. The strategic shift towards dried flower products and cost management has positioned Cann Group to be more competitive in the market as it enters FY26 with a focus on maximizing revenue and achieving an EBITDA-positive outcome.
Cann Group Limited reported a significant reduction in its net loss for the year ended 30 June 2025, with a 56% improvement compared to the previous year. This improvement is attributed to effective cost management, resulting in a 35% reduction in operating expenses. Despite a 27% decline in sales revenue due to a shift in product mix from oils to dried flowers, the company saw a 30% increase in dried flower tonnage sold and a 17% increase in sales for its Botanitech brand. The financial results indicate a positive trajectory for Cann Group as it continues to adapt to market changes and improve its operational efficiency.
Cann Group Limited reported a record production of 2.05 tonnes of dried flower in Q4 2025, marking a 41% increase from the previous quarter and contributing to a full-year production of 5.94 tonnes. The company achieved an 8% increase in sales, reaching $2.51 million for the quarter, and improved its net operating cash outflows by 13% compared to the prior quarter. With new debt and equity funding secured, Cann Group is poised for continued growth, focusing on restructuring its balance sheet and maximizing revenue as it enters FY2026.